MicroRNA‑720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1

Zhang,Yu; Su,Yueying; Zhao,Yabing; Lv,Guoqiang; Luo,Ying

doi:10.3892/mmr.2017.7732

MicroRNA‑720 inhibits pancreatic cancer cell proliferation and invasion by directly targeting cyclin D1

Authors:
- Yu Zhang
- Yueying Su
- Yabing Zhao
- Guoqiang Lv
- Ying Luo
View Affiliations

Affiliations: Department of General Surgery, Yongcheng City People's Hospital, Yongcheng, Henan 476600, P.R. China, Department of Hepatobiliary Surgery, Chinese PLA General Hospital, Beijing 100853, P.R. China
Published online on: October 5, 2017 https://doi.org/10.3892/mmr.2017.7732
Pages: 9256-9262

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pancreatic cancer is the fourth leading cause of cancer‑associated deaths in Western countries, and ranks sixth among cancer‑associated diseases, with the highest mortality rate in China. Deregulation of micro (miR) RNA may contribute to the occurrence and progression of numerous cancers, including pancreatic cancer. In particular, deregulation of microRNA‑720 (miR‑720) has been reported in various types of human cancer. However, the expression and biological role of miR‑720 in pancreatic cancer remains to be elucidated. The present study aimed to investigate the expression and functional role of miR‑720 in pancreatic cancer and determine the underlying regulatory mechanism. The results demonstrated that miR‑720 was expressed at low levels in pancreatic cancer tissue samples and cell lines. Upregulating miR‑720 suppressed pancreatic cancer cell proliferation and invasion in vitro. Additionally, cyclin D1 (CCND1) was identified as the direct target gene of miR‑720 in pancreatic cancer. Furthermore, CCND1 was significantly upregulated in pancreatic cancer tissues and inversely correlated with miR‑720 expression. Furthermore, CCND1 re‑expression partially abrogated the inhibitory effects of miR‑720 on pancreatic cancer cells. Overall, miR‑720 may act as a tumor suppressor by directly targeting CCND1 in pancreatic cancer.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res. 25:10–21. 2013.PubMed/NCBI
3	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
4	Modolell I, Guarner L and Malagelada JR: Vagaries of clinical presentation of pancreatic and biliary tract cancer. Ann Oncol. 10 Suppl 4:S82–S84. 1999. View Article : Google Scholar
5	Cartwright T, Richards DA and Boehm KA: Cancer of the pancreas: Are we making progress? A review of studies in the US Oncology Research Network. Cancer Control. 15:308–313. 2008. View Article : Google Scholar : PubMed/NCBI
6	Paulson AS, Cao HS Tran, Tempero MA and Lowy AM: Therapeutic advances in pancreatic cancer. Gastroenterology. 144:1316–1326. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ansari D, Gustafsson A and Andersson R: Update on the management of pancreatic cancer: Surgery is not enough. World J Gastroenterol. 21:3157–3165. 2015. View Article : Google Scholar : PubMed/NCBI
8	Puleo F, Maréchal R, Demetter P, Bali MA, Calomme A, Closset J, Bachet JB, Deviere J and Van Laethem JL: New challenges in perioperative management of pancreatic cancer. World J Gastroenterol. 21:2281–2293. 2015. View Article : Google Scholar : PubMed/NCBI
9	Greer JB, Lynch HT and Brand RE: Hereditary pancreatic cancer: A clinical perspective. Best Pract Res Clin Gastroenterol. 23:159–170. 2009. View Article : Google Scholar : PubMed/NCBI
10	Szafranska AE, Davison TS, John J, Cannon T, Sipos B, Maghnouj A, Labourier E and Hahn SA: MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene. 26:4442–4452. 2007. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: Target recognition and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
12	Wang Q, Wei L, Guan X, Wu Y, Zou Q and Ji Z: Briefing in family characteristics of microRNAs and their applications in cancer research. Biochim Biophys Acta. 1844:191–197. 2014. View Article : Google Scholar : PubMed/NCBI
13	Li M, Fu W, Wo L, Shu X, Liu F and Li C: miR-128 and its target genes in tumorigenesis and metastasis. Exp Cell Res. 319:3059–3064. 2013. View Article : Google Scholar : PubMed/NCBI
14	Kaplan BB, Kar AN, Gioio AE and Aschrafi A: MicroRNAs in the axon and presynaptic nerve terminal. Front Cell Neurosci. 7:1262013. View Article : Google Scholar : PubMed/NCBI
15	Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T and Chen P: MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3. Tumour Biol. 37:14813–14824. 2016. View Article : Google Scholar : PubMed/NCBI
16	Yoo HI, Kim BK and Yoon SK: MicroRNA-330-5p negatively regulates ITGA5 expression in human colorectal cancer. Oncol Rep. 36:3023–3029. 2016. View Article : Google Scholar : PubMed/NCBI
17	Zeng Y, Zhu J, Shen D, Qin H, Lei Z, Li W, Liu Z and Huang JA: MicroRNA-205 targets SMAD4 in non-small cell lung cancer and promotes lung cancer cell growth in vitro and in vivo. Oncotarget. 8:30817–30829. 2017.PubMed/NCBI
18	Zhou Y, Wu D, Tao J, Qu P, Zhou Z and Hou J: MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 47:423–432. 2013. View Article : Google Scholar : PubMed/NCBI
19	Bhardwaj A, Singh S and Singh AP: MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs. Mol Cell Pharmacol. 2:213–219. 2010.PubMed/NCBI
20	Li LZ, Zhang CZ, Liu LL, Yi C, Lu SX, Zhou X, Zhang ZJ, Peng YH, Yang YZ and Yun JP: miR-720 inhibits tumor invasion and migration in breast cancer by targeting TWIST1. Carcinogenesis. 35:469–478. 2014. View Article : Google Scholar : PubMed/NCBI
21	Tang Y, Lin Y, Li C, Hu X, Liu Y, He M, Luo J, Sun G, Wang T, Li W and Guo M: MicroRNA-720 promotes in vitro cell migration by targeting Rab35 expression in cervical cancer cells. Cell Biosci. 5:562015. View Article : Google Scholar : PubMed/NCBI
22	Wang X, Kuang Y, Shen X, Zhou H, Chen Y, Han Y, Yuan B, Zhou J, Zhao H, Zhi Q and Xue X: Evaluation of miR-720 prognostic significance in patients with colorectal cancer. Tumour Biol. 36:719–727. 2015. View Article : Google Scholar : PubMed/NCBI
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Xu Y, Liu T and Gao J: Effects of antisense cyclin D1 expressing vector on the cell growth and apoptosis of pancreatic carcinoma. Zhonghua Bing Li Xue Za Zhi. 27:348–351. 1998.(In Chinese). PubMed/NCBI
25	Yan L, Wang Y, Wang ZZ, Rong YT, Chen LL, Li Q, Liu T, Chen YH, Li YD, Huang ZH and Peng J: Cell motility and spreading promoted by CEACAM6 through cyclin D1/CDK4 in human pancreatic carcinoma. Oncol Rep. 35:418–426. 2016. View Article : Google Scholar : PubMed/NCBI
26	Lee Y, Ko D, Min HJ, Kim SB, Ahn HM, Lee Y and Kim S: TMPRSS4 induces invasion and proliferation of prostate cancer cells through induction of Slug and cyclin D1. Oncotarget. 7:50315–50332. 2016. View Article : Google Scholar : PubMed/NCBI
27	Mizuguchi Y, Takizawa T, Yoshida H and Uchida E: Dysregulated miRNA in progression of hepatocellular carcinoma: A systematic review. Hepatol Res. 46:391–406. 2016. View Article : Google Scholar : PubMed/NCBI
28	Liu H, Wang H, Liu X and Yu T: miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells. Biochem Biophys Res Commun. 472:346–352. 2016. View Article : Google Scholar : PubMed/NCBI
29	Ren ZG, Dong SX, Han P and Qi J: miR-203 promotes proliferation, migration and invasion by degrading SIK1 in pancreatic cancer. Oncol Rep. 35:1365–1374. 2016. View Article : Google Scholar : PubMed/NCBI
30	Trehoux S, Lahdaoui F, Delpu Y, Renaud F, Leteurtre E, Torrisani J, Jonckheere N and Van Seuningen I: Micro-RNAs miR-29a and miR-330-5p function as tumor suppressors by targeting the MUC1 mucin in pancreatic cancer cells. Biochim Biophys Acta. 1853:2392–2403. 2015. View Article : Google Scholar : PubMed/NCBI
31	Xia X, Zhang K, Cen G, Jiang T, Cao J, Huang K, Huang C, Zhao Q and Qiu Z: MicroRNA-301a-3p promotes pancreatic cancer progression via negative regulation of SMAD4. Oncotarget. 6:21046–21063. 2015. View Article : Google Scholar : PubMed/NCBI
32	Li L, Li B, Chen D, Liu L, Huang C, Lu Z, Lun L and Wan X: miR-139 and miR-200c regulate pancreatic cancer endothelial cell migration and angiogenesis. Oncol Rep. 34:51–58. 2015. View Article : Google Scholar : PubMed/NCBI
33	Zhong Y and Yi C: MicroRNA-720 suppresses M2 macrophage polarization by targeting GATA3. Biosci Rep. 36:pii: e003632016. View Article : Google Scholar
34	Li X, Huo X, Li W, Yang Q, Wang Y and Kang X: Genetic association between cyclin D1 polymorphism and breast cancer susceptibility. Tumour Biol. 35:11959–11965. 2014. View Article : Google Scholar : PubMed/NCBI
35	Betticher DC, Heighway J, Hasleton PS, Altermatt HJ, Ryder WD, Cerny T and Thatcher N: Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer. 73:294–300. 1996. View Article : Google Scholar : PubMed/NCBI
36	Kumari S, Puneet, Prasad SB, Yadav SS, Kumar M, Khanna A, Dixit VK, Nath G, Singh S and Narayan G: Cyclin D1 and cyclin E2 are differentially expressed in gastric cancer. Med Oncol. 33:402016. View Article : Google Scholar : PubMed/NCBI
37	Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ, Mongan NP and Persson JL: Expression of cyclin d1 and its association with disease characteristics in bladder cancer. Anticancer Res. 33:5235–5242. 2013.PubMed/NCBI
38	Gansauge S, Gansauge F, Ramadani M, Stobbe H, Rau B, Harada N and Beger HG: Overexpression of cyclin D1 in human pancreatic carcinoma is associated with poor prognosis. Cancer Res. 57:1634–1637. 1997.PubMed/NCBI
39	Li YJ and Ji XR: Relationship between the expression of beta-cat, cyclin D1 and c-myc and the occurance and biological behavior of pancreatic cancer. Zhonghua Bing Li Xue Za Zhi. 32:238–241. 2003.(In Chinese). PubMed/NCBI
40	Kornmann M, Danenberg KD, Arber N, Beger HG, Danenberg PV and Korc M: Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. Cancer Res. 59:3505–3511. 1999.PubMed/NCBI